Correlations Between Executive Functioning And Go-nogo Tasks And Event-related Potentials (p300) In Healthy Subjects

Abstract

PURPOSE: To study the correlations between electrophysiological parameters (P300 amplitude and latency), executive functioning and go-nogo scores in healthy subjects. METHODS: 49 healthy Flemish subjects (21 men and 28 women) from 20 to 80yrs participated in this study. Executive functioning and go-nogo tasks were investigated using subtests of the "Test for Attentional Performance-Mobility version" (TAP-M). Electrophysiological parameters, including P300 latency and amplitude, were elicited using a 2-stimuli visual oddball paradigm. Correlations were studied between P300 amplitude, P300 latency, results of neuropsychological subtests (correct answers, false answers and reaction time), age and education. RESULTS: In a linear regression model with correct answers on the executive function task as dependent variable, and P300 amplitude, P300 latency, age and education as factors, the overall effect was statistically significant (Anova: df=4; F=4.509; P=0.004). The factor P300 amplitude reached significance (t=2.406; P=0.020), while the other factors did not. For the go-nogo task, Spearman rank correlation was weak but significant between errors and reaction time (r=-0.308; P=0.031). Discussion: According to the literature, correlation between P300 amplitude and correct answers was expected for the go-nogo task; however our results did not show any correlation between these two parameters. This could be explained by different probabilities between the oddball paradigm (20% target and 80% non-target) and the go-nogo task (same probability for the 2 stimulus). Another reason might be that in the go-no, in addition to the target detection, inhibitory processes are involved to withhold responding to the non-target stimulus (nogo stimulus). CONCLUSION: Significant dependence was found between executive function task and electrophysiological parameter (P300 amplitude) in normal controls. Supported by Merck Serono Grant.